*Review* **Progress in Isoindolone Alkaloid Derivatives from Marine Microorganism: Pharmacology, Preparation, and Mechanism**

**Sijin Hang 1,†, Hui Chen 2,†, Wenhui Wu 1, Shiyi Wang 3, Yiwen Fang 4, Ruilong Sheng 5, Qidong Tu 6,\* and Ruihua Guo 1,7,8,\***



**Abstract:** Compound **1** (SMTP-7, also FGFC1), an isoindolone alkaloid from marine fungi *Starchbotrys longispora* FG216 and fungi *Stachybotrys microspora* IFO 30018, possessed diverse bioactivities such as thrombolysis, anti-inflammatory and anti-oxidative properties, and so on. It may be widely used for the treatment of various diseases, including cerebral infarction, stroke, ischemia/reperfusion damage, acute kidney injury, etc. Especially in cerebral infarction, compound **1** could reduce hemorrhagic transformation along with thrombolytic therapy, as the traditional therapies are accompanied with bleeding risks. In the latest studies, compound **1** selectively inhibited the growth of NSCLC cells with EGFR mutation, thus demonstrating its excellent anti-cancer activity. Herein, we summarized pharmacological activities, preparation of staplabin congeners—especially compound **1**—and the mechanism of compound **1,** with potential therapeutic applications.

**Keywords:** FGFC1; thrombus; fibrinolytic; *Stachybotrys longispora* FG216; *Stachybotrys microspora* IFO 30018
